Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The primary study objective is to determine if subjects experiencing an acute ischemic stroke
due to large vessel occlusion, treated with combined IV t-PA and Solitaire Revascularization
Device within 6 hours of symptom onset have less stroke-related neurological disability (mRS)
than those subjects treated with IV t-PA alone